Beth Brooks

1.1k total citations
13 papers, 582 citations indexed

About

Beth Brooks is a scholar working on Oncology, Sensory Systems and Molecular Biology. According to data from OpenAlex, Beth Brooks has authored 13 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Sensory Systems and 6 papers in Molecular Biology. Recurrent topics in Beth Brooks's work include Hearing, Cochlea, Tinnitus, Genetics (7 papers), Cancer therapeutics and mechanisms (5 papers) and Lung Cancer Research Studies (5 papers). Beth Brooks is often cited by papers focused on Hearing, Cochlea, Tinnitus, Genetics (7 papers), Cancer therapeutics and mechanisms (5 papers) and Lung Cancer Research Studies (5 papers). Beth Brooks collaborates with scholars based in Canada, United States and Netherlands. Beth Brooks's co-authors include Bruce Carleton, Colin J.D. Ross, Shahrad R. Rassekh, Michael R. Hayden, Kristin R. Knight, Henk Visscher, Marie‐Pierre Dubé, Andrew Brown, Paul Rogers and Michael Phillips and has published in prestigious journals such as Nature Genetics, PLoS ONE and Cancer.

In The Last Decade

Beth Brooks

13 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beth Brooks Canada 10 220 206 146 132 103 13 582
Vikas Malhotra India 8 109 0.5× 92 0.4× 161 1.1× 153 1.2× 44 0.4× 32 548
Renzo Lazzarini Italy 9 138 0.6× 51 0.2× 86 0.6× 29 0.2× 15 0.1× 11 333
G. Bonatz Germany 13 113 0.5× 72 0.3× 216 1.5× 49 0.4× 17 0.2× 21 624
Madhu P. Menon United States 15 215 1.0× 12 0.1× 215 1.5× 50 0.4× 18 0.2× 39 781
Cristina Mangas Spain 15 165 0.8× 5 0.0× 339 2.3× 62 0.5× 30 0.3× 42 748
Jim McGill Australia 15 29 0.1× 43 0.2× 306 2.1× 17 0.1× 155 1.5× 34 829
Maya Suzuki Japan 9 149 0.7× 9 0.0× 106 0.7× 34 0.3× 29 0.3× 35 359
G Fumagalli Italy 12 326 1.5× 9 0.0× 91 0.6× 75 0.6× 6 0.1× 26 501
Thomas A. Fey United States 12 22 0.1× 31 0.2× 197 1.3× 26 0.2× 17 0.2× 24 422
András Telekes Hungary 10 218 1.0× 9 0.0× 148 1.0× 63 0.5× 8 0.1× 24 531

Countries citing papers authored by Beth Brooks

Since Specialization
Citations

This map shows the geographic impact of Beth Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Brooks more than expected).

Fields of papers citing papers by Beth Brooks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Brooks. The network helps show where Beth Brooks may publish in the future.

Co-authorship network of co-authors of Beth Brooks

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Brooks. A scholar is included among the top collaborators of Beth Brooks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Brooks. Beth Brooks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Lee, Jong Wook, Beth Brooks, Katrina Hueniken, et al.. (2024). TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer. Journal of Pharmacology and Experimental Therapeutics. 392(2). 100057–100057. 2 indexed citations
2.
Brooks, Beth, Shahrad R. Rassekh, Wei Xu, et al.. (2023). Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children. Therapeutic Drug Monitoring. 45(3). 345–353. 4 indexed citations
3.
Tanoshima, Reo, Beth Brooks, Shahrad R. Rassekh, et al.. (2023). Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update. Therapeutic Drug Monitoring. 45(6). 714–730. 3 indexed citations
4.
Luo, Chunqiao, Joshua Millstein, Kristin R. Knight, et al.. (2021). Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. The Lancet Child & Adolescent Health. 5(4). 274–283. 52 indexed citations
5.
6.
7.
Drögemöller, Britt I., Galen E.B. Wright, Cody Lo, et al.. (2019). Pharmacogenomics of Cisplatin‐Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research. Clinical Pharmacology & Therapeutics. 106(2). 350–359. 21 indexed citations
8.
Drögemöller, Britt I., Beth Brooks, Jose Gerard Monzon, et al.. (2018). Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. Clinical Cancer Research. 24(8). 1866–1871. 28 indexed citations
9.
Brooks, Beth & Kristin R. Knight. (2017). Ototoxicity monitoring in children treated with platinum chemotherapy. International Journal of Audiology. 57(sup4). S62–S68. 44 indexed citations
10.
Pussegoda, Kusala, Colin J.D. Ross, Henk Visscher, et al.. (2013). Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children. Clinical Pharmacology & Therapeutics. 94(2). 243–251. 89 indexed citations
11.
Dionne, François, Craig Mitton, Shahrad R. Rassekh, et al.. (2011). Economic impact of a genetic test for cisplatin-induced ototoxicity. The Pharmacogenomics Journal. 12(3). 205–213. 15 indexed citations
12.
Ross, Colin J.D., Marie‐Pierre Dubé, Beth Brooks, et al.. (2009). Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics. 41(12). 1345–1349. 231 indexed citations
13.
Henry, David H., Beth Brooks, Jonas Kügler, et al.. (2006). Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.. PubMed. 1(4). 252–60. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vikas Malhotra Breakdown of academic impact, for papers by Renzo Lazzarini Breakdown of academic impact, for papers by G. Bonatz Breakdown of academic impact, for papers by Madhu P. Menon Breakdown of academic impact, for papers by Cristina Mangas Breakdown of academic impact, for papers by Jim McGill Breakdown of academic impact, for papers by Maya Suzuki Breakdown of academic impact, for papers by G Fumagalli Breakdown of academic impact, for papers by Thomas A. Fey Breakdown of academic impact, for papers by András Telekes
Rankless by CCL
2026